Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Professor of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Michael J. Mauro, MD, is leader of the Myeloproliferative Neoplasms Program and professor of medicine at Memorial Sloan Kettering Cancer Center in New York, NY. After receiving his BS in biology from Dartmouth College and his MD from the Geisel School of Medicine, both in Hanover, NH, he completed residency and fellowship training at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York.
Before joining Memorial Sloan Kettering Cancer Center, Dr Mauro was on the faculty of Oregon Health & Science University in Portland for 13 years, where he directed the Chronic Myeloid Leukemia (CML) Clinical Trial Program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML.
Dr Mauro’s clinical expertise is in treating patients with CML and other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis, as well as less common conditions such as eosinophilic and mast cell disorders. His research interests are focused on the development of novel agents for CML, increasing the options for treatment-free remission/functional cure in CML, and the identification and management of tyrosine kinase inhibitor–related adverse events (specifically cardiovascular events). He holds positions on the boards of the International Chronic Myeloid Leukemia Foundation, The MAX Foundation, and the Leukemia & Lymphoma Society.